Sodium Dichloroacetate

Sodium Dichloroacetate
Product Name Sodium Dichloroacetate
CAS No.: 2156-56-1
Catalog No.: CFN90889
Molecular Formula: C2HCl2NaO2
Molecular Weight: 150.9 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Targets: p53 | Mdm2 | p21
Source: The peels of Punica granatum L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Sodium dichloroacetate is a drug with potential for treating patients with stroke and head injury. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3; it is cytoprotective to some colorectal cancer cells under hypoxic conditions.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Food Res Int.2022, 157:111207.
  • J Neuroinflammation.2020, 17(1):75.
  • Appl. Sci.2020, 10(20), 7323.
  • Front Plant Sci.2017, 8:723
  • Antioxidants (Basel).2022, 11(10):1929.
  • J Sci Food Agric.2023, 103(1):213-220.
  • Molecules.2023, 28(16):6025.
  • Korean Journal of Plant Resources2021, 34(1):52-58.
  • Chin. Med.J.Res. Prac.2017, 31(4)
  • Molecules.2023, 28(13):4971.
  • Succinic acid

    Catalog No: CFN99100
    CAS No: 110-15-6
    Price: $30/20mg
    Fumaric acid

    Catalog No: CFN99201
    CAS No: 110-17-8
    Price: $30/20mg
    Malic acid

    Catalog No: CFN90558
    CAS No: 6915-15-7
    Price: $30/20mg
    Malic acid 4-Me ester

    Catalog No: CFN97130
    CAS No: 66178-02-7
    Price: Inquiry(manager@chemfaces.com)
    Tartaric acid

    Catalog No: CFN93181
    CAS No: 87-69-4
    Price: Inquiry(manager@chemfaces.com)
    Citric acid

    Catalog No: CFN98551
    CAS No: 77-92-9
    Price: $30/20mg
    Triethyl citrate

    Catalog No: CFN91520
    CAS No: 77-93-0
    Price: $30/20mg
    Hydroxycitric acid

    Catalog No: CFN90798
    CAS No: 6205-14-7
    Price: Inquiry(manager@chemfaces.com)
    Mannitol

    Catalog No: CFN93001
    CAS No: 87-78-5
    Price: $30/20mg
    Lactacystin

    Catalog No: CFN00121
    CAS No: 133343-34-7
    Price: Inquiry(manager@chemfaces.com)
    Cancer Lett. 2010 Nov 1;297(1):75-83.
    Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia.[Pubmed: 20537792 ]

    METHODS AND RESULTS:
    We examined the effect of hypoxia on apoptosis of human colorectal cancer (CRC) cells in vitro and in vivo. All cell lines tested were susceptible to hypoxia-induced apoptosis. Sodium Dichloroacetate (DCA) treatment caused significant apoptosis under normoxia in SW480 and Caco-2 cells, but these cells displayed decreased apoptosis when treated with DCA combined with hypoxia, possibly through HIF-1alpha dependent pathways. DCA treatment also induced significantly increased growth of SW480 tumor xenografts, and a decrease in TUNEL positive nuclei in hypoxic but not normoxic regions of treated tumors.
    CONCLUSIONS:
    Thus DCA is cytoprotective to some CRC cells under hypoxic conditions, highlighting the need for further investigation before DCA can be used as a reliable apoptosis-inducing agent in cancer therapy.
    Oncotarget. 2014 Jun; 5(12): 4347–4360.
    Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3[Pubmed: 24962518 ]

    METHODS AND RESULTS:
    The anti-leukemic activity of the mitochondria-targeting small molecule Sodium Dichloroacetate (DCA), used alone and in association with the small molecule inhibitor of the p53/MDM2 interaction Nutlin-3, was analyzed in primary B-chronic lymphocytic leukemia (B-CLL) samples (n=22), normal peripheral blood cells (n=10) and in p53wild-type EHEB, JVM-2, JVM-3 B lymphoblastoid cell lines. DCA exhibited a dose-dependent anti-leukemic activity in both primary B-CLL and B leukemic cell lines with a functional p53 status and showed a synergistic cytotoxic activity when used in combination with Nutlin-3. At the molecular level, DCA positively regulated p53 activity, as documented by post-transcriptional modifications of p53 protein, and synergized with Nutlin-3 in increasing the expression of the p53-target genes MDM2, PUMA, TIGAR and in particular p21. The potential role of p21 in mediating the DCA+Nutlin-3 anti-leukemic activity was underscored in knocking-down experiments. Indeed, transfection of leukemic cells with p21 siRNAs significantly decreased the DCA+Nutlin-3-induced cytotoxicity.
    CONCLUSIONS:
    Taken together, our data emphasize that DCA is a molecule that merits to be further evaluated as a chemotherapeutic agent for B-CLL, likely in combination with other therapeutic compounds.
    Fundam Appl Toxicol. 1996 Jul;32(1):87-95.
    Absence of mutagenic effects of sodium dichloroacetate.[Pubmed: 8812237]
    Sodium Dichloroacetate (DCA) is a drug with potential for treating patients with stroke and head injury. Conflicting evidence has been published on the mutagenic potential of DCA.
    METHODS AND RESULTS:
    A series of genetic tests for mutagenicity and clastogenicity was carried out on pharmaceutical grade DCA. Four types of mutagenicity test were included, with and without metabolic activation where appropriate. These studies included: (i) Salmonella and Escherichia coli mutation (Ames) test, (ii) thymidine kinase locus forward mutation in L5178Y mouse lymphoma cells, (iii) tests for chromosomal aberrations in Chinese hamster ovary cells, and (iv) and in vivo rat bone marrow erythroid micronucleus test. In each study, there was no evidence of mutagenic activity attributable to DCA. It is possible that the present test material, of pharmaceutical grade, has fewer impurities than materials studied in previous reports.
    CONCLUSIONS:
    These data extend, and in some cases contradict, previous published reports on DCA.
    6''-O-Acetylsaikosaponin D

    Catalog No: CFN95090
    CAS No: 64340-45-0
    Price: $288/5mg
    Neochlorogenic acid methyl ester

    Catalog No: CFN95190
    CAS No: 123410-65-1
    Price: $198/5mg
    Cuscutamine

    Catalog No: CFN95323
    CAS No: 122170-93-8
    Price: $318/5mg
    Foliachinenoside C

    Catalog No: CFN95361
    CAS No: 1041180-87-3
    Price: $368/5mg
    3',8-Dihydroxyvestitol

    Catalog No: CFN95384
    CAS No: 122587-87-5
    Price: $413/5mg
    6alpha-Hydroxydehydropachymic acid

    Catalog No: CFN95412
    CAS No: 176390-67-3
    Price: $413/5mg
    3beta-(alpha-L-Arabinopyranosyloxy)urs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester

    Catalog No: CFN95459
    CAS No: 435269-07-1
    Price: $318/20mg
    Otobaphenol

    Catalog No: CFN95476
    CAS No: 10240-16-1
    Price: $318/10mg
    Taxezopidine H

    Catalog No: CFN95562
    CAS No: 205440-23-9
    Price: $318/5mg
    Methyl nomilinate

    Catalog No: CFN95576
    CAS No: 77887-51-5
    Price: $318/5mg